MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens

PLoS One. 2012;7(12):e49952. doi: 10.1371/journal.pone.0049952. Epub 2012 Dec 5.

Abstract

Chickens lack the retinoic acid-inducible gene I (RIG-I) and sense avian influenza virus (AIV) infections by means of the melanoma differentiation-associated gene 5 product (chMDA5). Plasmid-driven expression of the N-terminal half of chMDA5 containing the caspase activation and recruitment domains [chMDA5(1-483)] triggers interferon-β responses in chicken cells. We hypothesized that mimicking virus infection by chMDA5(1-483) expression may enhance vaccine-induced adaptive immunity. In order to test this, the potential genetic adjuvant properties of chMDA5(1-483) were evaluated in vivo in combination with a suboptimal quantity of a plasmid DNA vaccine expressing haemagglutinin (HA) of H5N1 AIV. Co-administration of the HA plasmid with plasmid DNA for chMDA5(1-483) expression resulted in approximately 10-fold higher HA-specific antibody responses than injection of the HA plasmid mixed with empty vector DNA as control. Accordingly, compared with HA DNA vaccination alone, the chMDA5(1-483)-adjuvanted HA DNA vaccine mediated enhanced protection against a lethal H5N1 challenge infection in chickens, with reduced clinical signs and cloacal virus shedding. These data demonstrate that innate immune activation by expression of signaling domains of RIG-I-like receptors can be exploited to enhance vaccine efficacy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chickens / virology*
  • DEAD-box RNA Helicases / genetics
  • DEAD-box RNA Helicases / immunology*
  • Influenza A Virus, H5N1 Subtype / isolation & purification*
  • Influenza Vaccines / administration & dosage*
  • Influenza in Birds / genetics
  • Influenza in Birds / prevention & control*
  • Influenza in Birds / virology
  • Plasmids
  • RNA, Viral / isolation & purification
  • Vaccines, DNA / administration & dosage*

Substances

  • Influenza Vaccines
  • RNA, Viral
  • Vaccines, DNA
  • DEAD-box RNA Helicases

Grants and funding

This work was funded by the Swiss Federal Veterinary Office (grant number 1.07.09; www.bvet.admin.ch) and by the EU FP6 project FUPATH (grant number 044220; cordis.europa.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.